Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biotage and Peptide Synthesis

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
CEM claim to won a “patent dispute” with Biotage.

CEM Corporation has recently published a press release claiming to have won a “patent dispute” with Biotage. The so called “patent dispute” relates to Biotage’s filing of opposition against certain patents of CEM in Europe (Germany, France, Italy and Great Britain) and Japan, because Biotage believes that the patents as originally granted give CEM a broader protection than CEM is entitled to.

In April 2013 the Japanese Patent Office found that CEM’s patent, relating to microwave assisted solid phase peptide synthesis, is invalid.

Also the European Patent Office found that the scope of the corresponding European patent should be restricted.

The decisions by both patent offices were taken in response to the requests filed by Biotage. The decisions are open to appeal by both parties.

Biotage’s instruments for microwave assisted organic chemistry have been used in the scientific community since the late 1990s. Scientists took advantage of these early Biotage instruments to carry out microwave-assisted peptide synthesis more than ten years ago, even before CEM filed their first patent application in this field.

As early as in 2002, Professor Gogoll and his team at Uppsala University published an article entitled “Rapid Microwave-Assisted Solid Phase Peptide Synthesis” using a Biotage instrument.

This is part of Biotage’s heritage in the peptide synthesis business, which led the company to put more dedicated efforts into the peptide synthesis area, culminating in the launch of the Biotage® Syro Wave™ in 2010.

In 2012 Biotage launched the successful Biotage® Initiator+ Alstra™, which is the company’s latest automated microwave peptide synthesizer.

“Biotage of course respects third party patent rights. I am surprised that CEM claims that we are in a dispute and even more that they claim to have won. This is an ongoing discussion on what the fair scope of these patents is, if any. The CEM patents concerned do not cover Biotage’s line of instruments for microwave assisted peptide synthesis. All synthesis protocols preinstalled in the Biotage instruments are outside the patents, even as originally granted. The situation is the same with the corresponding US patents. This means that customers all over the world can continue to use Biotage’s microwave peptide synthesizers with the preinstalled methods. Peptide synthesis is a product area where Biotage will continue to grow and deliver exciting products to the market.” says Torben Jörgensen, CEO of Biotage.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biotage Achieves ISO 14001:2004 Certification
This certificate is an international standard for an environmental management system (EMS) that helps businesses such as Biotage control and improve practices that are potentially harmful to the environment.
Tuesday, June 14, 2016
New Methods for the Extraction of Key Compounds for Clinical, Environmental and Forensic Applications
A new series of application notes utilizing the industry-standard RapidTrace® SPE Workstation for medicinal and analytical chemistry have been released.
Monday, January 10, 2011
Peptide Synthesis Webinar Series Introduces Second Installment: Synthesis of Difficult Peptide Sequences
Biotage announces the second installment in its series of webinars focusing on peptide synthesis.
Friday, October 29, 2010
Peptide Synthesis Webinar Series Introduces Second Installment: Synthesis of Difficult Peptide Sequences
Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announced the second installment in its series of webinars focusing on peptide synthesis.
Wednesday, October 27, 2010
Biotage Announces Research Collaboration with University of Copenhagen for Peptide Synthesis
Collaborations aims to develop new applications on the Biotage Syro Wave in the field of synthetic peptide and protein chemistry.
Thursday, May 13, 2010
Biotage Awarded Patent for Flash Purification Method Development and Optimization
The Company has been awarded U.S. patent 7686959: Control system and Method for Flash Separation.
Wednesday, April 21, 2010
Biotage Introduces EVOLUTE WCX: Now Providing a Total Solution for Basic Compounds
Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, today announced the further expansion of its successful family of products with the launch of Evolute WCX.
Wednesday, March 17, 2010
Biotage Joins Forces with MultiSynTech and Enters the Peptide Synthesis Business
Biotage enters agreements concerning both the distribution rights for MultiSynTechs systems and the establishment of a joint development project.
Tuesday, February 24, 2009
Biotage Makes a Change in Top Management after Business Area President Resigns
David Patteson, President of the business area Discovery Chemistry will leave the company on 1 April 2006.
Tuesday, February 28, 2006
Biotage Receives its Largest Order to Date
Instruments, which originate from the recently acquired company Argonaut, will be used by chemists to enhance the processes used in the development of pharmaceuticals.
Friday, August 12, 2005
Biotage expands European presence

Wednesday, April 09, 2003
Scientific News
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.
Game Changing Antibacterial Drug Research
Researchers publish report on the synthesis of a newly discovered “game-changing” antibiotic, Teixobactin.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
New Way of Displaying 3D Molecular Structures
Metal-organic frameworks provide a new platform for solving the structure of hard-to-study samples.
Agent Blocks Pain Without Morphine's Side Effects
Scientists have synthesised a molecule with specific pain-relief properties and has shown its efficacy in mice.
Cutting the Cost of Drug-Building Chemicals
EPFL scientists have developed a method to produce aryl-containing amines in a cheap and easily scalable way.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!